VolitionRx Ltd
VNRX
31 hedge funds and large institutions have $12.2M invested in VolitionRx Ltd in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 4 closing their positions.
42% more call options, than puts
Call options by funds: $170K | Put options by funds: $120K
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.01% less ownership
Funds ownership: 0.57% → 0.55% (-0.01%)
9% less funds holding
Funds holding: 34 → 31 (-3)
33% less capital invested
Capital invested by funds: $18.3M → $12.2M (-$6.05M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIM
Lagoda Investment Management
New York
|
+$101K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$16.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$14K |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$10.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.82K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$207K |
| 2 |
Barclays
London,
United Kingdom
|
-$68.5K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$67K |
| 4 |
GBA
Garrison Bradford & Associates
New York
|
-$47K |
| 5 |
Millennium Management
New York
|
-$33.2K |
VNRX Hedge Fund Activity: Q2 2022 in Review
31 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in VolitionRx Ltd (VNRX) for Q2 2022, worth a combined $12.2M — down 33% from $18.3M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of VNRX and 1 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 10 added.
The largest buyer was Lagoda Investment Management, adding an estimated $101K. The largest seller was Morgan Stanley, cutting an estimated $207K.
- 31 institutional investors held VolitionRx Ltd (VNRX) as of Q2 2022, down from 34 in Q1 2022.
- Funds reported $12.2M of VolitionRx Ltd stock for Q2 2022, down 33% quarter-over-quarter.
- 1 fund opened new VolitionRx Ltd positions in Q2 2022 and 4 closed out, a net change of -3 holders.
- The largest VolitionRx Ltd buyer in Q2 2022 was Lagoda Investment Management, an estimated $101K added.
- The largest VolitionRx Ltd seller in Q2 2022 was Morgan Stanley, an estimated $207K sold.
Based on aggregated 13F filings for Q2 2022.